Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product

MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (⁶⁸Ga-PSMA-11 Injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).
The submission has been made to the Danish Medicines Agency (DKMA) in its capacity as a reference Competent Authority of a European member state. The DKMA will coordinate and lead the evaluation of Telix’s MAA for TLX591-CDx on behalf of Denmark as well as a selection of European countries, nominated by Telix. These countries reflect the major European markets for Telix’s prostate cancer imaging product.In accordance with the current European Association of Urology (EAU) guidelines on prostate cancer imaging, Telix is seeking a product approval in Europe for TLX591-CDx for the indication of imaging patients with elevated prostate-specific antigen (PSA) after radical prostatectomy or radiation therapy. This indication, which is broadly termed biochemical recurrence (BCR), is reported to occur in 20-40% and 30-50% of men who have undergone prostatectomy or radiation therapy with curative intent, respectively.¹Telix EU President and founder of Telix’s wholly owned subsidiary Advanced Nuclear Medicine Ingredients (ANMI) Mr. Ludovic Wouters said, “We are delighted to have submitted our first marketing authorisation application for a commercially significant market. We approached the DKMA as our reference Competent Authority due to their extensive experience in reviewing medical imaging and radiopharmaceutical product submissions. We’ve consulted with the DKMA since early 2019 and have gained valuable feedback based on a clear understanding of the clinical need for this technology.”Telix’s European MAA for TLX591-CDx is the result of an extensive pan-European collaboration and includes clinical data obtained in over 2,000 patients from both prospective and retrospective studies at leading European nuclear medicine centres. Institutions contributing clinical data include Ospedale Sant’Orsola (Bologna, Italy), Ordensklinikum, St Vincent’s Hospital (Linz, Austria), University Hospital of RWTH University (Aachen, Germany), Cliniques Universitaires Saint-Luc UCL (Brussels, Belgium) and Nuclear Medicine Biophysics Paris Hôpital Tenon (Paris, France).Telix CEO Dr. Chris Behrenbruch said that, “Getting to the point of submitting a marketing authorisation based on extensive clinical data and a robust manufacturing package, is the rarely achieved goal of every small biopharmaceutical company. We have the added advantage that use of our technology has also now been written into clinical practice guidelines in Europe and the United States, so we expect rapid adoption post-approval. In addition to recognizing the clinical partners that have contributed to this submission, I’d like to acknowledge the outstanding pioneering work by scientists and clinicians at Heidelberg University in Germany and the Deutsches Krebsforschungszentrum (German Cancer Research Centre), whom we have to thank for the opportunity to bring this exciting technology to market for the benefit of patients.”_____________________________
¹ Kolodziej M. Management of Biochemically Recurrent Prostate Cancer Following Local Therapy. Am J Manag Care. 2014; 20:S273-S281.About TLX591-CDxTLX591-CDx (kit for the preparation of ⁶⁸Ga-PSMA-11 injection) is a proprietary formulation of PSMA-HBED-CC (PSMA-11), a novel small molecule agent targeting prostate-specific membrane antigen (PSMA), originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum (German Cancer Research Centre, DKFZ).² The “cold kit” format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, ideally suited for the radiopharmacy setting. Currently, TLX591-CDx is available for investigational use only. TLX591-CDx is not currently approved in any regulatory jurisdiction including the United States and European Union.About Telix Pharmaceuticals LimitedTelix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.Important InformationThis announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Chief Executive Officer.________________________________
² Eder, et al. Bioconjugate Chem Apr 18, 2012; 23(4): 688-97. 
Telix Corporate Contact
Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email:

Telix Investor Relations
Dr. David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: